ONO PHARMACEUTICAL CO.,LTD.

July 12, 2016

Amgen Receives Approval for Kyprolis® (Carfilzomib) For Expanded Indication for the Treatment of Relapsed Multiple Myeloma

On July 3, 2016, Amgen (NASDAQ:AMGN) announced that the European Commission (EC) has approved a variation to the marketing authorization for Kyprolis® (carfilzomib) to include use in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy. The extended indication marks the second approval for Kyprolis® by the EC in less than a year.

For further information, visit the link below to the website for press release distributed by Amgen.

http://www.amgen.com/media/news-releases/2016/07/european-commission-approves-extended-indication-for-amgens-kyprolis-carfilzomib-for-the-treatment-of-relapsed-multiple-myeloma-patients/

In Japan, Ono Pharmaceutical Co., Ltd. (ONO) entered into an exclusive license agreement with Onyx, now a wholly-owned subsidiary of Amgen, in September 2010 to develop and commercialize two compounds from Onyx's proteasome inhibitor development program, carfilzomib (for injection) and oprozomib (orally administered) for all oncology indications. ONO received a Manufacturing and Marketing Approval for of Kyprolis® (carfilzomib) for the indication of relapsed or refractory multiple myeloma on July 4, 2016.

Contact
ONO PHARMACEUTICAL CO., LTD.
Corporate Communications
public_relations@ono.co.jp